Details
Stereochemistry | RACEMIC |
Molecular Formula | C14H12O8 |
Molecular Weight | 308.2403 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(O)CC2=C(CO1)C(=O)C3=C(O2)C=C(O)C(O)=C3C(O)=O
InChI
InChIKey=FCYKAQOGGFGCMD-UHFFFAOYSA-N
InChI=1S/C14H12O8/c1-14(20)3-8-5(4-21-14)11(16)9-7(22-8)2-6(15)12(17)10(9)13(18)19/h2,15,17,20H,3-4H2,1H3,(H,18,19)
Fulvic acid is primarily studied for its effects on plants and soil. Fulvic acid is an organic and natural electrolyte. Depending on the situation, Fulvic acid can act as an electron donor or acceptor and an oxidizer or reducer. Fulvic acid has exhibited the ability to enhance the availability and adsorption of nutrients as well as prolong their time of residence. In the chick animal model Fulvic acid disturbed the processing of procollagen II in articular cartilage. Fulvic acid has being shown to attenuate homocysteine-induced cyclooxygenase-2 expression in human monocytes. Fulvic acid, the main active principle of Shilajit (a natural substance found mainly in the Himalayas), blocks tau self-aggregation, opening an avenue toward the study of Alzheimer's therapy. People take fulvic acid by mouth for brain disorders such as Alzheimer’s disease, as well as respiratory tract infections, cancer, fatigue, heavy metal toxicity, and preventing a condition in which the body tissues do not receive enough oxygen (hypoxia).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25888188 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21931500 |
Primary | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Fulvic acid supplementation and selenium deficiency disturb the structural integrity of mouse skeletal tissue. An animal model to study the molecular defects of Kashin-Beck disease. | 1993 Feb 1 |
|
Influence of fulvic acid on the collagen secretion of bovine chondrocytes in vitro. | 1999 Jul |
|
Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer's disease. | 2011 |
|
Microarray analysis of immediate-type allergy in KU812 cells in response to fulvic acid. | 2011 Mar |
Patents
Sample Use Guides
Fulvic Acid comes in liquid and powder form: The recommended maintenance dose of Fulvic acid is 1 - 2 Ounces per day based on one teaspoon per 20 pounds (preferably split ½ in the morning and ½ in the mid-afternoon) – 6 teaspoons = 1 ounce = 2 Tablespoons.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25888188
To test the effects of Fulvic acid (FA) on homocysteine-induced COX-2
expression in monocytes, human primary monocytes and
U937 cells were pretreated with FA at concentrations of
0.5, 1, 5, and 10 ug/mL for 4 h, and then stimulated with
homocysteine (200 uM) for 4 h in the presence of FA. Pretreating monocytes
with FA at a concentration of 1 or 10 ug/mL
reduced the homocysteine-induced PGE2 secretion.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
1807 (Number of products:114)
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB128622
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
PRIMARY | |||
|
5359407
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
PRIMARY | |||
|
C005023
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
PRIMARY | |||
|
XII14C5FXV
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
PRIMARY | |||
|
100000154409
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
PRIMARY | |||
|
XII14C5FXV
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
PRIMARY | |||
|
1314310
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
PRIMARY | RxNorm | ||
|
479-66-3
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
PRIMARY | |||
|
DTXSID00861991
Created by
admin on Sat Dec 16 01:26:33 GMT 2023 , Edited by admin on Sat Dec 16 01:26:33 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD